Understand the source comparison
Best Peptides for Prediabetes: Full Comparison
The comparison below covers the most-studied research peptides for metabolic dysfunction, their primary mechanisms, evidence base, and practical limitations. Tirzepatide analogs Dual GLP-1/GIP receptor agonist. Slows gastric emptying, stimulates glucose-depend
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The comparison below covers the most-studied research peptides for metabolic dysfunction, their primary mechanisms, evidence base, and practical limitations.
- Tirzepatide analogs
- Dual GLP-1/GIP receptor agonist. Slows gastric emptying, stimulates glucose-dependent insulin secretion
- Phase III trials in diabetic populations; research-grade versions lack human prediabetic data
- 2.5–15mg weekly (subcutaneous)
- GI side effects (nausea, vomiting, diarrhea) in 30–45% during titration; theoretical pancreatitis risk
- Most robust mechanism for insulin sensitization but requires prescriber oversight due to GI tolerability issues
- AOD-9604
- Growth hormone fragment. Stimulates lipolysis via beta-3 adrenergic receptors without affecting glucose or IGF-1
- Animal models and small Phase II obesity trials; no dedicated prediabetic studies
- 300–500mcg daily (subcutaneous)
- Minimal reported adverse events; lacks long-term human safety data
- Indirect metabolic benefit through fat reduction; not a primary insulin sensitizer
- MOTS-c
- Mitochondrial-derived peptide. Activates AMPK, increases GLUT4 translocation in muscle tissue
- Preclinical rodent models; one human exercise study (n=27)
- 5–15mg weekly (subcutaneous)
- Unknown. Human data extremely limited
- Promising AMPK activation but lacks replication in controlled human trials
- Semaglutide (research-grade)
- GLP-1 receptor agonist. Delays gastric emptying, enhances satiety signaling, improves beta-cell function
- FDA-approved as Ozempic/Wegovy for diabetes and obesity; research versions identical molecule
- 0.25–2.4mg weekly (subcutaneous)
- GI adverse events, rare pancreatitis, contraindicated with MEN2 or thyroid carcinoma history
- Gold-standard incretin mimetic but research-grade lacks FDA batch oversight
- Hexarelin
- Growth hormone secretagogue. Stimulates GH/IGF-1 release, improves cardiac function
- Preclinical models; limited human trials in heart failure populations
- 100–200mcg 2–3x daily (subcutaneous)
- Cortisol elevation, potential desensitization with chronic use
- Not an insulin sensitizer. Indirect metabolic effects through GH pathway
- This table isolates mechanism from marketing. The compounds with the strongest insulin-sensitizing evidence (tirzepatide analogs, semaglutide) work through incretin pathways that are well-documented in diabetic populations but understudied in prediabetic cohorts. MOTS-c shows the most direct AMPK activation but lacks Phase II human data. AOD-9604 and hexarelin address body composition secondarily. They're not metabolic-first interventions.
- The pattern we've observed across peptide research: GLP-1 and GIP agonists produce measurable glycemic improvements within 8–12 weeks, whereas AMPK activators and mitochondrial peptides require 16–24 weeks to show statistically significant changes in fasting insulin or HOMA-IR scores. Timeline matters when structuring intervention protocols.